SingularityNET Partners With Shivom to Advance Genomic Medical Research & Analytics

Announcing a new alliance to advance AI-driven medicine to improve the quality of life for global citizens.

Today, we’re excited to introduce a new partnership with Shivom, a decentralized platform creating the world’s largest genomic data hub. We will be combining blockchain, AI, and genomic research into a cross-disciplinary, information-theoretic technology to achieve advanced, personalized medical analytics.

Integrating Our Platforms Will Provide Clear Synergies

Shivom’s decentralized platform provides an integrated solution for patients and genome data donors, in which genomes can be sequenced and securely stored. This creates an open-web marketplace that service providers, such as pharmaceutical companies, research organizations, governments, patient-support groups and insurance companies, can use. Service providers will be able to add their apps and services alongside genomic data analytics and personalized medicine to the platform.

Because the SingularityNET AI team is involved with a number of research projects — including those that look at the genomics of longevity in an effort to support medical research aimed at maximizing the healthy human lifespan — connecting our data sources and platform capabilities will bring many synergies.

The goal of our partnership is to connect our networks and maximize the respective science and engineering teams of each organization.

What to Expect From Our Partnership

Once the integration is complete, AI agents on SingularityNET that require genomic or other biological data to complete tasks will be able to request datasets from Shivom.

In return, if a Shivom customer requests that AI analytics are to be performed on the medical data they have uploaded, the Shivom network will be able to request the technology from SingularityNET.

We expect to accelerate these services through our combined networks, providing customers, researchers, and medical professionals with a clear and enhanced understanding of personalized health analytics.

This cross-network activity will occur with automatic conversion between SingularityNET AGI Tokens and Shivom Tokens, with appropriate encryption within data sharing, as well as the ability for cross-network rating and reputation management. We expect to create the underpinnings of these services, along with multiple further innovations in AI-driven genomic and medical analytics.

“We are excited to work with SingularityNET. AI approaches are well suited to model the complex dependencies in the regulatory landscape of our genome and can help to predict an individual’s probability of developing certain diseases. Such information should be made actionable. As such, we are confident that AI will play a central role in our platform for achieving greater depth in the interpretation of genetic information such as how an individual’s genes may impact their lifestyle decisions or help their healthcare providers to design of potential therapies.” — Shivom Co-Founder and CEO, Dr. Axel Schumacher “We are enthused to have the opportunity to support Shivom’s vision of next-era genomic research. The Shivom vision synergizes beautifully with the SingularityNET vision; the integration of Shivom’s technology, tools, and data with our SingularityNET mind-network will add more scope and intelligence into the field of personalized medical analytics.I. Together, we can achieve great things for medical science by utilizing high-quality datasets, SingularityNET’s algorithms and customer base for biomedical analytics services, and Shivom’s genomics-focused software.” — SingularityNET CEO, Dr. Ben Goertzel

Next Steps

As our teams begin long-term integration efforts, SingularityNET CEO Ben Goertzel will be chronicling additional use-cases and synergies through an upcoming post on our blog. Stay tuned!

In the meantime, be sure to join our Community Forum, which allows you to chat directly with our AI team, as well as developers and researchers from around the world.